Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | PTAFR | P25105 | 3/20 | 0.35 |
| ▸ | NMT2 | O60551 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775513 | 0.85 | LMNA (0.37) | CHRNA7ACP1PTAFRNMT2NMT1 | |
| SCHEMBL5335896 | 0.83 | ACP1 (0.42) | CHRNA7ACP1PTAFRNMT2NMT1 | |
| SCHEMBL6698442 | 0.82 | BCHE (0.46) | — | |
| SCHEMBL4793700 | 0.81 | KMT2A (0.32) | — | |
| SCHEMBL4775733 | 0.81 | FES (0.35) | GBA1NOS1CYP3A4CYP2C9 | |
| SCHEMBL4772034 | 0.78 | HTR7 (0.42) | — | |
| SCHEMBL4777348 | 0.76 | GBA1 (0.36) | TDP1L3MBTL1TLR8TLR7GBA1 | |
| SCHEMBL28753167 | 0.73 | KMT2A (0.45) | — | |
| SCHEMBL4794435 | 0.73 | CHRNA7 (0.35) | CHRNA7PTAFRTDP1L3MBTL1SERPINE1 | |
| SCHEMBL4775915 | 0.73 | ADORA2A (0.41) | GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513524-A4 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2008-09-03 | — | — | EP | disclosed |
| US-7220758-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060252792-A1 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-11-09 | — | — | US | disclosed |
| US-7125890-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1513524-A2 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M Innovative Properties Company (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20050032830-A1 | Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors | 3M INNOVATIVE PROPERTIES COMPANY | 2005-02-10 | — | — | US | disclosed |
| US-6797718-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-28 | — | — | US | disclosed |
| US-20040010007-A1 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-15 | — | — | US | disclosed |
| WO-2003103584-A2 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252792-A1 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | IL2, IL4, MYD88 | CHRNA7 4538/4885ACP1 2322/4885PTAFR 2371/4885 |
| US-20050032830-A1 | Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors | IL2, IFNG, TSLP | CHRNA7 4849/4885ACP1 2157/4885PTAFR 2122/4885 |
| US-20040010007-A1 | Ether substituted imidazopyridines | IL2, IL4, MYD88 | CHRNA7 4538/4885ACP1 2322/4885PTAFR 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.